Quest Diagnostics, the nation’s leading provider of diagnostic information services, has announced that it will partner with GRAIL, Inc., a healthcare company whose mission is to detect cancer early, to support Galleri, GRAIL’s multi-cancer early detection blood test.

“Quest Diagnostics maintains approximately 2,200 patient service centers and, through its ExamOne business, 5,000 mobile phlebotomists with expertise in at-home visits. Quest’s phlebotomy network will help provide blood specimen collection for Galleri in the United States once the test becomes available this year.”

“An earlier version of Galleri demonstrated the ability to detect more than 50 types of cancers — over 45 of which lack recommended screening tests today — with a low false positive rate of less than 1%. When a cancer signal is detected, Galleri can determine the location of the cancer signal with high accuracy, all from a single blood draw.”